Dr Reddy's Is Knocked Back On US NuvaRing And Copaxone Rivals

15 Aug 2019

Dr Reddy’s has received a further CRL from the US Food and Drug Administration over its application for a generic rival to Merck Sharp & Dohme’s NuvaRing contraceptive, along with a CRL for its version of Teva’s Copaxone.

Rejection — Dr Reddy’s Has Received A Pushback On Two US Applications • Source: Shutterstock

Dr. Reddy's has received a complete response letter from the US Food and Drug Administration over the Indian firm’s US application for a generic version of

Merck Sharp & Dohme's NuvaRing (etonogestrel/ethinylestradiol) vaginal ring contraceptive brand.